A Longitudinal Study of the IgG Antibody Response to HIV-1 P17 Gag Protein in HIV-1+ Patients with Haemophilia: Titre and Avidity

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1993 Sep 1

PMID 8370162

Citations 6

Authors

D Chargelegue

C M OToole

B T Colvin

Affiliations

Soon will be listed here.

Abstract

The IgG response to HIV-1 p17 gag protein was studied for up to 6 years in 12 HIV-1-infected patients with haemophilia, who had seroconverted between 1982 and 1985. To assess any prognostic value, p17 IgG titres were compared with p24 IgG titres, CD4 cell counts and p24 antigenaemia. p17 IgG avidity index was also examined. A strong similarity was found between the IgG titre to HIV-1 p17 and that to p24. In patients who developed AIDS the decline in p17 IgG titres could precede by several years the drop in CD4 cells to under 200 cells/microliters; whereas some long-term asymptomatic patients (CDCII) had increasing p17 IgG titres and stable CD4 cell counts. Declining p17 and p24 IgG titres were not always associated with an increase in p24 antigenaemia. IgG titres were found to be better predictors of disease progression than CD4 cell counts or p24 antigenaemia. Patients who developed AIDS during the study were also characterized by a lower p17 IgG avidity than patients who remained asymptomatic. This result suggests that IgG avidity could have prognostic relevance and be of importance for host resistance to AIDS onset.

Citing Articles

Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection.

French M, Abudulai L, Fernandez S Vaccines (Basel). 2015; 1(3):328-42.

PMID: 26344116 PMC: 4494226. DOI: 10.3390/vaccines1030328.

Decreasing Proportion of Recent Infections among Newly Diagnosed HIV-1 Cases in Switzerland, 2008 to 2013 Based on Line-Immunoassay-Based Algorithms.

Schupbach J, Niederhauser C, Yerly S, Regenass S, Gorgievski M, Aubert V PLoS One. 2015; 10(7):e0131828.

PMID: 26230082 PMC: 4521810. DOI: 10.1371/journal.pone.0131828.

Rate and incidence estimates of recent human immunodeficiency virus type 1 infections among pregnant women in Sao Paulo, Brazil, from 1991 to 2002.

de Freitas Oliveira C, Ueda M, Yamashiro R, Rodrigues R, Sheppard H, Brigido L J Clin Microbiol. 2005; 43(3):1439-42.

PMID: 15750127 PMC: 1081217. DOI: 10.1128/JCM.43.3.1439-1442.2005.

Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.

Cole K, Murphey-Corb M, Narayan O, Joag S, Shaw G, Montelaro R J Virol. 1998; 72(10):7852-9.

PMID: 9733822 PMC: 110105. DOI: 10.1128/JVI.72.10.7852-7859.1998.

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Cole K, Rowles J, Jagerski B, Murphey-Corb M, Unangst T, Clements J J Virol. 1997; 71(7):5069-79.

PMID: 9188572 PMC: 191740. DOI: 10.1128/JVI.71.7.5069-5079.1997.

References

Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J . Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983; 220(4599):868-71. DOI: 10.1126/science.6189183. View

OToole C, Lowdell M, Chargelegue D, Colvin B . Decline in CTL and antibody responses to HIV-1 p17 and p24 antigens in HIV-1-infected hemophiliacs irrespective of disease progression. A 5-year follow-up study. AIDS Res Hum Retroviruses. 1992; 8(8):1361-8. DOI: 10.1089/aid.1992.8.1361. View

Barin F, McLane M, Allan J, Lee T, Groopman J, Essex M . Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 1985; 228(4703):1094-6. DOI: 10.1126/science.2986291. View

Holtzman E, Yaari S, Goldbourt U . Serum cholesterol and the risk of colorectal cancer. N Engl J Med. 1987; 317(2):114. DOI: 10.1056/NEJM198707093170211. View

Chou M, Lee T, Hatzakis A, Mandalaki T, McLane M, Essex M . Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs. J Infect Dis. 1988; 157(4):805-11. DOI: 10.1093/infdis/157.4.805. View

Lange J, de Wolf F, Krone W, Danner S, Coutinho R, Goudsmit J . Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS. 1987; 1(3):155-9. View

Smith D, Johnson K . Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988; 67(1):31-40. DOI: 10.1016/0378-1119(88)90005-4. View

Mathiesen T, Sundqvist V, Albert J, Ohlsson E, Wahren B . Acid hydrolysis of serum samples to increase detection of HIV antigen. J Virol Methods. 1988; 22(2-3):143-8. DOI: 10.1016/0166-0934(88)90097-3. View

Vitetta E, Fernandez-Botran R, Myers C, Sanders V . Cellular interactions in the humoral immune response. Adv Immunol. 1989; 45:1-105. DOI: 10.1016/s0065-2776(08)60692-6. View

10.

Broliden P, Rosen J, Jondal M, Wahren B . Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients. Clin Exp Immunol. 1989; 76(2):216-21. PMC: 1541818. View

11.

Joly P, Guillon J, Mayaud C, Plata F, Theodorou I, Denis M . Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes. J Immunol. 1989; 143(7):2193-201. View

12.

Wen Y, Duan S, Howard C, Frew A, Steward M . The affinity of anti-HBc antibodies in acute and chronic hepatitis B infection. Clin Exp Immunol. 1990; 79(1):83-6. PMC: 1534737. DOI: 10.1111/j.1365-2249.1990.tb05131.x. View

13.

Ferns R, Partridge J, Spence R, Hunt N, Tedder R . Epitope location of 13 anti-gag HIV-1 monoclonal antibodies using oligopeptides and their cross reactivity with HIV-2. AIDS. 1989; 3(12):829-34. DOI: 10.1097/00002030-198912000-00008. View

14.

Mehta S, Rupprecht K, Hunt J, Kramer D, McRae B, Allen R . Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection. AIDS Res Hum Retroviruses. 1990; 6(4):443-54. DOI: 10.1089/aid.1990.6.443. View

15.

Converse P, Fehniger T, Ehrnst A, Strannegard O, Britton S . Immune responses to fractionated cytomegalovirus (CMV) antigens after HIV infection. Loss of cellular and humoral reactivity to antigens recognized by HIV-, CMV+ individuals. Clin Exp Immunol. 1990; 82(3):559-66. PMC: 1535510. DOI: 10.1111/j.1365-2249.1990.tb05490.x. View

16.

Panagiotidi C, Bowcock S, Aronstam A, Wadsworth J, Weber J . Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection. BMJ. 1991; 302(6767):23-6. PMC: 1668741. DOI: 10.1136/bmj.302.6767.23. View

17.

Allain J, Laurian Y, Einstein M, Braun B, Delaney S, Stephens J . Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance. Blood. 1991; 77(5):1118-23. View

18.

Steward M, Stanley C, DiMarchi R, Mulcahy G, Doel T . High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease. Immunology. 1991; 72(1):99-103. PMC: 1384343. View

19.

Del Prete G, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P . Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest. 1991; 88(1):346-50. PMC: 296040. DOI: 10.1172/JCI115300. View

20.

Shearer G, Clerici M . Early T-helper cell defects in HIV infection. AIDS. 1991; 5(3):245-53. DOI: 10.1097/00002030-199103000-00001. View